跳至主要内容
临床试验/JPRN-UMIN000010291
JPRN-UMIN000010291招募中2 期

Efficacy of transcatheter arterial chemoembolization (TACE) with miriplatin for multiple hepatocellular carcinoma refractory or inappropriate to conventional TACE - Efficacy of transcatheter arterial chemoembolization (TACE) with miriplatin for multiple hepatocellular carcinoma refractory or inappropriate to conventional TACE

Department of Surgery, Graduate School of Medicine Kyoto University0 个研究点目标入组 20 人开始时间: 2013年4月1日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients with another active cancer 2) Patients with extrahepatic metastasis 3) Patients with prior surgical reconstruction of the biliary tract or prior endoscopic treatment of ampulla of vater 4) Patients with clinically significant refractory ascites or pleural effusion 5) Patients with hepatic encephalopathy 6) Patients with severe co-morbidity such as cardiac failure and renal failure 7) Patients with a medical history of severe hypersensitivity 8) Patients who are pregnant, lactating or are suspected to be pregnant. 9) Patients who are concluded to be inappropriate to participate in this study by their physicians

研究者

发起方
Department of Surgery, Graduate School of Medicine Kyoto University

相似试验